The anthracycline drug doxorubicin is among the most used—and useful—
chemotherapeutics. While doxorubicin is highly effective in the treatment of various …

Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

Clinical use of doxorubicin (DOX) is limited because of its cardiotoxicity, referred to as DOX-
induced cardiomyopathy (DIC). Mitochondria-dependent ferroptosis, which is triggered by …

Background The past few decades have seen substantial improvements in cancer survival,
but concerns exist about long-term cardiovascular disease risk in survivors. Evidence is …

Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many
people perceive breast cancer to be the number one threat to women's health. CVD and …

Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …

Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.
Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer …

Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies
that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual …

Many cancer type-specific anticancer agents have been developed and significant
advances have been made toward precision medicine in cancer treatment. However …